券代码：002004 证券简称：华邦健康 公告编号：2025055 华邦生命健康股份有限公司 关于公司及子公司2026年度向银行等金融机构 申请授信额度及担保事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、概述 华邦生命健康股份有限公司（以下简称"公司"）于 2025 年 12 月 23 日通 过通讯表决的方式召开第九届董事会第四次会议，会议审议通过了《关于公司及 子公司 2026 年度向银行等金融机构申请授信额度及担保事项的议案》。 2026 年度公司及子公司拟向银行等金融机构申请综合授信的额度总计不超 过 131.54 亿元人民币，担保额度总计不超过 102.74 亿元人民币。综合授信用于 办理流动资金贷款、项目资金贷款、银行承兑汇票、国内信用证、打包贷款、应 收账款保理、进出口押汇、商业票据贴现、保函、售后回租等各种贷款及融资业 务。公司提请股东会授权公司法定代表人或总经理根据实际情况在前述总授信额 度内，办理公司及子公司的融资事宜，并签署有关与各金融机构发生业务往来的 相关各项法律文件。 授权期限自公司股东会审议批准之日起至 2026 ...

2、履行的审议程序：公司于 2025 年 12 月 23 日召开第九届董事会第四次会 议，审议通过了《关于预计 2026 年度开展远期结售汇业务和人民币对外汇期权 组合等业务的议案》，该议案尚需提交至公司 2026 年第一次临时股东会审议。 3、特别风险提示：公司开展远期结售汇业务和人民币对外汇期权组合等业 务不以投机为目的，主要为规避汇率出现较大波动时，汇兑损益对公司的经营业 绩会造成影响，但同时也存在一定的风险，敬请投资者注意投资风险。 一、交易情况概述 证券代码：002004 证券简称：华邦健康 公告编号：2025057 华邦生命健康股份有限公司 关于预计 2026 年度开展远期结售汇业务 和人民币对外汇期权组合等业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、交易目的、交易品种、交易工具、交易场所、交易金额：为了降低汇率 波动对华邦生命健康股份有限公司（以下简称"公司"）利润的影响及基于经营 战略的需要，使公司保持较为稳定的利润水平，并专注于生产经营，公司拟在银 行开展远期结售汇业务和人民币对外汇期权组合等业务。交易工具 ...

华邦生命健康股份有限公司 关于2026年度开展远期结售汇业务和人民币对外汇期权组 合等业务的可行性分析报告 一、公司开展远期结售汇业务和人民币对外汇期权组合等业务的背景 华邦生命健康股份有限公司（以下简称"公司"）因公司农化业务和原料药等 业务营业收入中外销占比大，公司在日常经营过程中会涉及外币业务。在外汇市 场汇率和利率波动的金融市场环境下，为适应外汇市场变化，防范外汇波动对公 司造成的不利影响，公司2026年拟开展远期结售汇业务和人民币对外汇期权组合 等业务，充分利用外汇衍生品的套期保值功能及成本锁定功能，实现以规避风险 为目的的资产保值，降低汇率波动对公司的影响。 1 四、公司开展远期结售汇业务和人民币对外汇期权组合等业务的主要条款 1、交易品种：金融机构提供的外汇远期、外汇掉期（互换）、外汇期权等 产品或上述产品的组合等。 二、公司开展远期结售汇业务和人民币对外汇期权组合等业务的概述 2、合约期限：与基础交易预测回款期限相匹配，一般不超过一年。 公司拟开展的外汇衍生品套期保值业务品种包括但不限于外汇远期、外汇期 权、外汇掉期（互换）等产品或上述产品的组合，以进行外汇套期保值和防范汇 率或利率风险为目的 ...

证券代码：002004 证券简称：华邦健康 公告编号：2025056 华邦生命健康股份有限公司 关于增加 2025 年度日常关联交易预计 及预计 2026 年度日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 公司于 2025 年 12 月 23 日通过通讯表决的方式召开第九届董事会第四次会 议和第九届董事会第一次独立董事专门会议，会议均审议通过了《关于增加 2025 年度日常关联交易预计及预计 2026 年度日常关联交易的议案》。现将增加 2025 年度日常关联交易预计及预计 2026 年度日常关联交易公告如下： 一、日常关联交易基本情况 （一）2025 年度日常关联交易概述 公司于 2024 年 12 月 10 日召开第八届董事会第二十一次会议，审议通过了 《关于增加2024年度日常关联交易预计及预计2025年度日常关联交易的议案》， 预计了 2025 年公司与关联方发生的各类日常关联交易及金额，关联董事张松山 先生、张海安先生、王榕先生已回避表决。并于 2024 年 12 月 26 日通过了 2024 年第一次临时股东大会审议。 公司本 ...

证券代码：002004 证券简称：华邦健康 公告编号：2025059 华邦生命健康股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 1 月 12 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2026 年 1 月 12 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2026 年 1 月 12 日 9:15 至 15:00 的任意时 间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 1 ...

Core Viewpoint - Huabang Health (002004.SZ) has announced the approval of several proposals regarding the issuance of non-public technology innovation exchangeable corporate bonds, which will be submitted for shareholder meeting review [1] Group 1: Bond Issuance Details - The company plans to issue exchangeable corporate bonds targeting professional institutional investors, with a total scale not exceeding 1 billion RMB (including 1 billion RMB) [1] - The bonds will be exchangeable for shares of Shandong Kaisheng New Materials Co., Ltd. (stock code: 301069.SZ) [1] - The specific issuance scale and timing will be determined by the board of directors based on the company's funding needs and market conditions, with authorization from the shareholder meeting [1] Group 2: Board Meeting Resolutions - The fourth meeting of the ninth board of directors reviewed and approved the proposals related to the bond issuance [1] - The proposals include the conditions for the issuance of the exchangeable bonds and the authorization for the board to handle related matters [1]

华邦生命健康股份有限公司 第九届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开及议案审议情况 华邦生命健康股份有限公司（以下简称"公司"）第九届董事会第四次会议通 知于 2025 年 12 月 19 日以电子邮件的形式发出，2025 年 12 月 23 日通过通讯表 决的方式召开，公司 6 名董事都参加了本次会议，会议的通知及召开符合《公司 法》及《公司章程》的规定，合法有效。会议由董事长张松山先生主持，经与会 各位董事认真讨论研究，审议并通过了相关议案。 证券代码：002004 证券简称：华邦健康 公告编号：2025054 （一）审议通过了《关于公司及子公司 2026 年度向银行等金融机构申请授 信额度及担保事项的议案》。 详见公司同日在《中国证券报》、《证券时报》、《上海证券报》及巨潮资讯网 （www.cninfo.com.cn）刊载的《关于公司及子公司 2026 年度向银行等金融机构 申请授信额度及担保事项的公告》（公告编号：2025055）。 表决结果：6 票赞成，0 票反对，0 票弃权。 本议案尚需提交至公司 ...

Core Insights - The fifth Chongqing Capital Market High-Quality Development Conference emphasized the importance of listed companies in driving the capital market's high-quality development, urging them to take on responsibilities in governance, innovation, and investor relations [1] Group 1: Listed Companies in Chongqing - As of now, Chongqing has 78 A-share listed companies with a market capitalization of approximately 1.3 trillion yuan [2] - In the first three quarters of 2025, these companies achieved operating revenue of 572.13 billion yuan and net profit of 32.96 billion yuan, with over 40% of firms experiencing growth in both metrics [2] - Chongqing's listed companies exhibit a "124+N" characteristic, with a national leading R&D investment of 14.768 billion yuan in the first half of 2025, a year-on-year increase of 42.1% [2][3] Group 2: Key Performance Indicators - Chongqing's listed companies have the largest asset scale in Central and Western China, reaching 40.173 billion yuan by the end of the third quarter of 2025, a 7% year-on-year increase [3] - The refinancing scale of these companies reached 13 billion yuan in the first three quarters of 2025, marking a 125.9% increase year-on-year, ranking second in Western China [3] - The number of companies with over 50% of revenue from overseas is second in Western China, with 7 companies achieving this in the first half of 2025 [3] Group 3: Unique Industry Characteristics - Several companies in Chongqing have made significant achievements in their respective industries, such as Sanfeng Environment issuing the first "Belt and Road" technology innovation green corporate bond in the country [4] - Chongqing Rural Commercial Bank has the largest asset scale among rural commercial banks nationwide, while companies like Giant Network and Chongqing Beer lead in their respective sectors [4] Group 4: Two Rivers New Area Development - The Two Rivers New Area has 37 listed companies, contributing approximately 55.15% of the city's operating revenue and 49.35% of net profit, despite representing only 37% of the total number of listed companies [6] - Since the implementation of the "merger and acquisition six guidelines," Chongqing has seen active mergers and acquisitions, with 12 companies completing 14 transactions worth 35.276 billion yuan in the first three quarters of 2025, a 637% increase year-on-year [6][7] Group 5: Recommendations for Future Development - The report suggests optimizing policy supply and reducing transaction costs for successful mergers, including offering preferential policies for projects that land in Chongqing and exploring the establishment of a "merger loan risk compensation fund" [7]

Core Insights - The fifth Chongqing Capital Market High-Quality Development Conference highlighted new opportunities for listed companies through mergers and acquisitions [1] - The "Chongqing Listed Companies Development Report (2025)" was released, serving as a comprehensive resource for the development of listed companies in Chongqing [1] Group 1: Company Performance - As of now, there are 78 A-share listed companies in Chongqing with a total market capitalization of approximately 1.3 trillion yuan [1] - In the first three quarters of 2025, Chongqing listed companies achieved a total operating income of 572.13 billion yuan and a net profit of 32.96 billion yuan, with over 40% of companies reporting growth in both metrics [1] - Chongqing listed companies exhibited a "124+N" characteristic, with a notable focus on R&D investment [1] Group 2: Key Metrics - Chongqing ranked first in the nation for R&D investment among listed companies, with a total of 14.77 billion yuan in R&D spending in the first half of 2025, representing a year-on-year increase of 42.1% [2] - The proportion of private listed companies in Chongqing increased from 50.9% at the end of 2020 to 60.3%, the highest among the four direct-controlled municipalities [2] - The number of manufacturing listed companies in Chongqing reached 48, accounting for 61.5% of the total, surpassing Beijing's 39.4% and Shanghai's 56.7% [2] Group 3: Regional Comparisons - Chongqing's listed companies have the largest asset scale in Central and Western China, reaching 4.0173 trillion yuan by the end of the third quarter of 2025 [2] - The refinancing scale of Chongqing listed companies was the second largest in Western China, with 13 billion yuan raised through private placements and convertible bonds, a year-on-year increase of 125.9% [2] - The number of companies with over 50% of revenue from overseas operations ranked second in Western China, with 7 companies achieving 31.39 billion yuan in overseas revenue in the first half of 2025 [2] Group 4: Future Outlook - The Chongqing municipal government is committed to building a multi-level capital market as part of its strategy to enhance the Western financial center, promoting the "Thoroughbred" action for company listings [3] - The Western Financial Research Institute aims to strengthen collaboration with various stakeholders to enhance research on listed companies and capital market development [3] - The annual publication of the "Chongqing Listed Companies Development Report" will continue to improve the recognition and penetration of the "Chongqing Listed Companies" financial brand [3]

Group 1 - The company, Huabang Life Health Co., Ltd., announced a non-public issuance of exchangeable bonds aimed at professional investors, with a total issuance size of 600 million RMB and a term of 3 years [2] - The exchangeable bonds, referred to as "25 Huabang EB," have been fully converted, resulting in a total of 0 bonds remaining, and will be delisted from the Shenzhen Stock Exchange on December 8, 2025 [3] - Following the completion of the bond conversion, the company holds 126,755,153 shares of Kaisheng New Materials Co., Ltd., representing 30.13% of its total share capital, without affecting its status as the controlling shareholder [4]